What Medicare beneficiaries need to consider during open enrollment

Medicare open enrollment, running from October 15 to December 7, is proceeding amidst an ongoing federal government shutdown, leading experts to advise beneficiaries to delay final 2026 coverage decisions due to potential difficulties accessing comprehensive information, despite CMS assurances of continued critical operations. This period is crucial for evaluating plan changes, as some carriers are expanding while others retract, and beneficiaries must carefully weigh options between Original Medicare and Medicare Advantage, which now offers more detailed information on supplemental benefits and provider networks. Concurrently, the Part D prescription drug market sees an increase in zero-premium plans but also rising deductibles, a shrinking overall plan count, and an increased 2026 out-of-pocket maximum of $2,100 for covered drugs, necessitating thorough review of prescription coverage.

Analysis

Medicare open enrollment for 2026 coverage commenced on October 15th amidst an ongoing federal government shutdown, which began October 1st. While the Centers for Medicare and Medicaid Services (CMS) asserts that "mission-critical activities" will continue, experts like Philip Moeller strongly advise beneficiaries to delay final decisions until the government reopens due to potential difficulties accessing comprehensive information, such as delays with 1-800-Medicare or specific Plan Finder queries. This creates an environment of heightened uncertainty regarding timely access to critical plan details.

The market for Medicare plans is dynamic, with some carriers expanding and others retracting from specific areas, underscoring the necessity for beneficiaries to actively shop for coverage. Beneficiaries must weigh the trade-offs between Original Medicare, which lacks an out-of-pocket cap on medical services and can be "increasingly unaffordable," and Medicare Advantage plans. Advantage plans offer supplemental benefits and now provide more detailed information on provider networks and benefits, though they often include access limitations and prior authorization requirements.

Significant changes are also evident in Medicare Part D prescription drug plans, with an increase in zero-premium options juxtaposed against rising annual deductibles and potentially higher co-pays. The overall number of Part D plans is shrinking, and the annual out-of-pocket maximum for covered drugs will increase to $2,100 in 2026, up from $2,000 in 2025. These shifts necessitate a thorough review of prescription coverage to assess overall annual costs, as out-of-pocket healthcare spending already represented 39% of Social Security income for beneficiaries in 2022.

Key Decisions for Investors

• Given the government shutdown, investors should advise clients to delay final Medicare coverage decisions until full information access is restored, leveraging the flexibility of the enrollment period.
• Emphasize thorough due diligence on Medicare Advantage and Part D plans, focusing on total annual costs, network limitations, and comprehensive prescription coverage, particularly given rising deductibles and the increased Part D out-of-pocket maximum.
• Consider the January 1st to March 31st Medicare Advantage open enrollment period as a strategic window for clients to review and adjust initial choices, especially if information was constrained during the primary enrollment.
• Monitor regional trends in Medicare carrier participation, as expansions or pullbacks can signal shifts in market competitiveness and plan availability, impacting long-term coverage options.